Journal
EMERGING INFECTIOUS DISEASES
Volume 23, Issue 3, Pages 491-495Publisher
CENTERS DISEASE CONTROL
DOI: 10.3201/eid2303.161034
Keywords
-
Categories
Funding
- US National Institutes of Health [R01A1089349, RO1A1087465, K23AI103044, D43TW007124]
- National Institutes of Health [K23A1083088, K24AI114444]
- Emory Center for AIDS Research [P30A1050409]
- Einstein/Montefiore Institute for Clinical and Translational Research [UL1 TR001073]
- Atlanta Clinical and Translational Science Institute [UL1TR000454]
Ask authors/readers for more resources
Although pyrazinamide is commonly used for tuberculosis treatment, drug-susceptibility testing is not routinely available. We found polynnorphisms in the pncA gene for 70% of multidrug-resistant and 96% of extensively drug resistant Mycobacterium tuberculosis isolates from South Africa and Georgia. Assessment of pyrazinamide susceptibility may be prudent before using it in regimens for drug resistant tuberculosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
